Then October 28, 2021, after the market closed, CareDx released third quarter 2021 financial results in which the Company disclosed that the U.S. Department of Justice ("DOJ") served a civil investigatory demand requesting documents in connection with a False Claims Act investigation. The DOJ is investigating business practices related to CareDx's kidney testing and phlebotomy services. The Company also disclosed that it received a subpoena from the U.S. Securities and Exchange Commission ("SEC") for similar issues, as well as certain accounting and public reporting practices, and the Company received an information request from an unnamed state agency. On this news, the Company's share price declined by $19.34 per share, or 27%, to close at $51.00 per share on October 29, 2021. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.